Clinical trial · no report yet · Phase 2
EVOKE-02
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
- NCT05186974 ↗
- Active not recruiting
- Gilead Sciences
- 30 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 13 | |
| Podcasts | 11 | |
| YouTube | 6 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Sacituzumab Govitecan-hziy (SG); Pembrolizumab; Carboplatin; Cisplatin
- Arms
- Sacituzumab Govitecan-hziy (SG) + Pembrolizumab (Cohort A) · Experimental
- SG + Pembrolizumab (Cohort B) · Experimental
- SG + Pembrolizumab + Carboplatin Safety Run-in · Experimental
- SG + Pembrolizumab + Cisplatin Safety Run-in (Optional) · Experimental
- SG + Pembrolizumab + Carboplatin or Cisplatin (Cohort C) · Experimental
- SG + Pembrolizumab + Carboplatin or Cisplatin (Cohort D) · Experimental
- SG + Pembrolizumab + Cisplatin (Cohort E) · Experimental
- Enrollment
- 193
- Primary outcomes
- Objective Response Rate as Assessed by Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
- Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) per Dose Level in the Safety Run-in Cohorts
- Sponsor
- Gilead Sciences with Merck Sharp & Dohme LLC
- Start
- May 30, 2022
- Primary completion
- Mar 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05186974 · updated Sep 11, 2026
Publications
linked from the registry- Reck M, Patel JD, Gray JE, Reguart N, Cobo M, Pradera JF, Felip E, Cappuzzo F, Garon EB, Neal JW, Mekan S, Safavi F, Fernando N, Zavodovskaya M, Jurgensmeier JM, Chisamore M, Cho BC. First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study. J Thorac Oncol. 2026 Mar;21(3):103509. doi: 10.1016/j.jtho.2025.10.016. Epub 2025 Oct 30. PubMed 41173143